VIDEO: Pelabresib can control platelet counts in essential thrombocythemia
Click Here to Manage Email Alerts
In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind a study presented at ASCO Annual Meeting, examining the effect of the BET inhibitor pelabresib on patients with essential thrombocythemia.
Gerds, assistant professor of medicine at Cleveland Clinic Taussig Cancer Institute, discussed the study, that found treatment with pelabresib (CPI-0610, MorphoSys) could allow significant control of platelet counts in patients with essential thrombocythemia.
“What we need in essential thrombocythemia are not just drugs that can control counts and symptoms, but can alter the disease’s course significantly,” Gerds said. “I think we have a key eye on a lot of the agents being developed in this space.”
Collapse
Read more about
Click Here to Manage Email Alerts